GLORIA MATTIUZZI, MD

PERSONAL SKILLS

PROFESIONAL SUMMARY

Strong 10 year background in Hematology & Oncology Supportive Care and Infectious Diseases Clinical Research

Experience in generating hypothesis driven research investigations

Extensive knowledge in all phases of drug development, from the initial company or investigator concept and protocol development through trial enrollment and conference abstracts, final manuscript

Broad experience on regulatory committees evaluating ethical aspects of clinical and non-clinical protocols and evaluating feasibility of clinical trials

Good understanding of areas such as biostatistics, regulatory, clinical pharmacology, pre-clinical toxicology

Ability to develop, analyze and interpret databases

Strong organization skills and leadership personality

Extensive experience presenting in national and international congresses, symposiums and in Grand Rounds at academic centers

Several years of experience as reviewer for Peer journal articles

Substantial experience writing abstracts and manuscripts, designing and preparing posters and slides presentations.

Teaching experience supervising fellows and post- doctoral fellows

Fluent in English and Spanish

CURRICULUM VITAE

Gloria N. Mattiuzzi, MD

CITIZENSHIP

United States

HOME ADDRESS

3830 Sun Valley

Houston, TX 77025

Phone: 832-***-**** (h)

713-***-**** (c)

Email: aczy5c@r.postjobfree.com

EDUCATION

Degree-Granting Education

Universidad Central de Venezuela, Caracas, Venezuela, Medico Cirujano, 1986, Medicine

Postgraduate Training

Rural Internship, Medicatura Rural Araira, Estado Miranda, Venezuela, 1/1986 12/1986

Clinical Internship, Internal Medicine, Hospital Dr. Jose Gregorio Hernandez, Caracas, Venezuela, 12/1986 12/1987

Clinical Residency, Internal Medicine, Hospital Dr. Domingo Luciani, Universidad Central de Venezuela, Caracas, Venezuela, 12/1987 12/1990

Fellowship, Infectious Disease, Infectious Disease Sec, Department of Medical Specialties, U. T. M. D. Anderson Cancer, Houston, TX, 9/1991 8/1994

CREDENTIALS

Board Certification

Venezuelan Board of Internal Medicine, 1/1991

EXPERIENCE/SERVICE

2011 – Present: Expert Consultant, Eisai

Academic projects / Manuscripts preparations, Leukemia Department The University of Texas MD Anderson Cancer Center. Houston, TX

2002 – 2011: Assistant Professor, Leader Supportive Care Program

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. Houston TX

2000 – 2001: Instructor,

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Other Appointments/Responsibilities

Private Practice Internist, Clinica La Floresta, Caracas, Venezuela, 1/1991 5/1991

Private Practice Physician, Unidad OncoHematologica, San Carlos de Bariloche, Argentina, 2/1996 7/1999

Consultantships

Eisai, Expert consultant. 2007 - Present

Institutional Committee Activities

Institutional Review Board 4, Associate Member, 9/2005 8/2006

Responsibilities: Oversee the regulations and ethical aspects of clinical and non-clinical protocols

The Transfusion Subcommittee, Alternate member, 9/2008 2011

Institutional Review Board 1, Associate Member, 9/2008 2011

Responsibilities: Oversee the regulations and ethical aspects of clinical and non-clinical protocols

CRC (Clinical Research Committee): Member, 2007-20011.

Responsibilities review and discus the feasibility of clinical trials.

HONORS AND AWARDS

Fujisawa Award for Achievement in Clinical Excellence, Fujisawa, 2000

Thomas J. Walsh Mycology Award, Focus on Fungal Infection Annual Meeting, 2006

RESEARCH

Protocols/ Investigator Initiated protocols

Funded

Principal Investigator, An open label, phase II study of intravenous itraconazole for prophylaxis of systemic fungal infections in patients with AML or MDS undergoing induction chemotherapy, DM00-152, 2000 2002, $265,000, Ortho Biotech

Principal Investigator, Open randomized study of intravenous itraconazole versus caspofungin for prophylaxis of systemic fungal infections in patients with AML or MDS undergoing induction chemotherapy, DM01-169, 2001 2003, $500,000, Ortho Biotech

Principal Investigator, Prospective Observational Study of Mylotarg (Gemtuzumab Ozagamicin) in Usual Care, DM02-286, 2002 2007, $9,600, Millennix INC

Co-Principal Investigator, A randomized study of Procrit versus no Procrit in newly diagnosed acute lymphocytic leukemia, ID02-591, 2002 2009, $492,000, Ortho Biotech

Principal Investigator, Amphotericin B Lipid Complex (ABELCET) in the treatment of patients with hematological malignancies and invasive fungal infections, RCR03-0917, 2003, $72,000, Enzon Pharmaceuticals, Inc.

Principal Investigator, Secondary Prophylaxis in Patients with Acute Leukemia and History of Invasive Fungal Infection, RCR03-0890, 2003, $92,000, Fujisawa

Principal Investigator, Breakthrough Fungal Infections in Patients with Hematological Malignancies Receiving Antifungal Prophylaxis: Analysis of Predictive Factors and Outcome, RCR03-0377, 2003 2004, $55,000, Pfizer

Principal Investigator, Retrospective observational review of high dose Ambisome in the treatment of documented invasive fungal infections in patients with hematologic malignancies, RCR04-0127, 2004 2007, $50,000, Gilead Sciences, Inc.

Principal Investigator, Invasive Fungal Infections Surveillance Initiative, PCR05-0300, 2005 2007, $50,000, Astellas pharmaceuticals

Principal Investigator, Prospective Observational Study of Acute Diarrhea in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome Receiving Cytarabine Containing Regimens, PCR03-0855, 2005 2007, $60,000, Astellas Pharmaceuticals

Co-Principal Investigator, Phase II, open, randomized comparative trial of two different schedules of palonosetron versus ondansetron for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine, 2005-0389, PI - Jorge Cortes, 2005 2009, $232,900, MGI Pharmaceuticals

Co-Principal Investigator, Assessment of iron overload in the development and outcome of infectious complications in patients with hematologic malignancies, 2006-0536, PI - Jorge Cortes, 2007 2009, $150,000, Novartis

Co-Principal Investigator, A randomized study of epoetin alfa (Procrit) versus no epoetin alfa (Procrit) in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing frontline myelosuppressive induction/consolidation chemotherapy, 2005-0890, PI - Jorge Cortes, 2008 2010, Ortho Biotech

Principal Investigator, Epidemiology of invasive aspergillosis in patients with hematologic malignancies, DR08-0371, 2008 present, $70,000, Merck

Co-Principal Investigator, Kinetics of 1,3 Beta-d glucan assay in patients with hematologic malignancies receiving voriconazole prophylaxis, 2008-0443, PI - Jorge Cortes, 2009, $56,000, Pfizer

Co-Principal Investigator, A multicenter registry study of anti-rasburicase antibodies in patients retreated with rasburicase (SR29142) in the context of relapsing leukemia/lymphoma who experienced subsequent hypersensitivity reaction(s) or loss of uricolytic activity: an immuno-monitoring observational study, 2009-0134, PI - Jorge Cortes, 2009 2010. $32,500, Sanofi-Aventis U.S.

Co-Principal Investigator, Phase II study of the pharmacokinetics of posaconazole prophylaxis in relapsed or refractory patients with acute leukemia, 2008-0793, PI - Jorge Cortes, 2009 2010, $250,000, Schering-Plough

Co-Principal Investigator, Phase II, open, randomized comparative trial ondansetron versus aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine, 2008-0615, PI - Jorge Cortes, 2009 2010, $400,000, Merck

Unfunded

Principal Investigator, Open label, phase II study of itraconazole versus voriconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia or myelodysplastic syndrome, ID03-0003, 2003

Principal Investigator, Causes of Death of Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome undergoing Induction Chemotherapy: Retrospective, RCR02-298, 2003 2004

Co-Principal Investigator, Fungal infections During Induction, Maintenance, and Intensification Chemotherapy in Patients with ALL receiving Hyper-CVAD, RCR03-0478, 2003 2011

Principal Investigator, Open randomized comparative trial of two different schedules of liposomal amphotericin B versus oral voriconazole for the prevention of invasive fungal infections, 2006-0536, 2006 2009

Principal Investigator, Predictors of ICU admission and survival in the ICU for patients with acute leukemia, DR07-0912, 2007 2011

Principal Investigator, Incidence of acute renal failure and frequency of dialysis in patients with acute leukemia, DR08-0183, 2008 2009

Co-Principal Investigator, A Prospective Randomized Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients with Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine, 2007-0797, PI - Emil Freireich, 2008 2011

Principal Investigator, Incidence of infections in patients with hematological malignancies receiving induction and salvage therapies: analysis of predictive factors and outcomes, DR08-0250, 2008 2011

Co-Principal Investigator, A prospective randomized comparative study of the effect on infections of radiated prophylactic white cell transfusions versus therapeutic radiated white cell transfusions, 2010-0468, PI - Emil J. Freireich, 2010 2011

Grant Reviewer/Service on Study Sections

Institutional Review Board 4, Associate Member, 9/2005 8/2006

Responsibilities: Oversee the regulations and ethical aspects of clinical and non-clinical protocols

Institutional Review Board 1, Associate Member, 9/2008 2011

Responsibilities: Oversee the regulations and ethical aspects of clinical and non-clinical protocols

CRC (Clinical Research Committee): Member, 2007-20011.

Responsibilities: review and discus the feasibility of clinical trials

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Anaissie EJ, Mattiuzzi GN, Miller CB, Noskin GA, Gurwith MJ, Mamelok RD, Pietrelli LA. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 42:606-11, 1998.

2. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 9:976-80, 2003.

3. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97:450-6, 2003.

4. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:581-9, 2004.

5. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39:199-205, 2004.

6. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:568-73, 2004.

7. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29:649-52, 6/2005.

8. Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 131(3):287-300, 11/2005.

9. Philip A, Odabasi Z, Mattiuzzi G, Paetznick VL, Tan SW, Warmington J, Rex JH, Ostrosky-Zeichner L. Syscan3, a kit for detection of anti-candida antibodies for diagnosis of invasive candidiasis. J Clin Microbiol 43:4834-4835, 2005.

10. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tu. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis 43:1031-9, 2006.

11. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad, II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50:143-7, 2006.

12. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohtgi N, Sepulveda C, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica 92 (09):1216-1223, 2007.

13. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Kantarjian H, Gonzalez V, Safdar A, Raad I. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 44:964-7, 2007.

14. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. J Clin Oncol 26(35):5684-8, 10/2008. e-Pub 10/2008.

15. Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, Heussel CP, Kahl C, Kiehl M, Lorenz J, Hof H, Mattiuzzi G. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 45(14):2462-72, 9/2009.

16. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1):93-7, 1/2010. e-Pub 10/2009.

17. Sever M, Verstovsek S, Erasmus J, Mattiuzzi GN. Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: Case report and review of the literature. Leuk Res 34(5):e133-6, 5/2010. e-Pub 1/2010.

18. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore) 89(4):236-44, 7/2010.

19. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116(17):4063-8, 9/2010. e-Pub 5/2010.

20. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116(24):5659-66, 12/2010. e-Pub 8/2010.

21. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19(1):19-26, 1/2011. e-Pub 12/2009.

22. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117(5):982-91, 3/2011. e-Pub 10/2010.

23. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a Randomized Clinical Trial. Cancer. e-Pub 7/2011.

24. EJ Freireich, B Lichtiger, G Mattiuzzi, F Martinez, V Reddy and J Kyle Wathen. A prospective, randomized, double-blind study, comparing unirradiated to irradiated white cell transfusions in acute leukemia patients. Leukemia (2013) 27, 861-865

25. Tlha Badar, Jorge Cortes,Gautam Borthakur, Susan O’Brien, William Wierda, Guillermo Garcia-Manero, Alessandra Ferrajoli, Tapan Kadia, Rebeca Poku, Hagop Kantarjian, Gloria Mattiuzzi. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Research Int 2015; 2015:497597.doi: 10.1155/2015/497597. Epub 2015 Jan 15

26. G. Mattiuzzi, Musa Yilmaz, Hagop Kantarjian, Gothan Borthakur, Marina Konopleva, Elias Jabbour, Yolanda Brown, Sherry Pierce, Jorge Cortes.Pharmacokinetic of Posaconazole Prophylaxis of patients with Acute Myelogenous Leukemia. Journal of Infection and Chemotherapy (2015)

Invited Articles

1. Mattiuzzi G, Alvarez R, Giles F. Treatment of Aspergillus Infections in BMT Patients. Antibiotic for Clinicians, Supplement 1: Fungal Infections in Hospitalized Patients. AFC 7:7-12, 2003.

2. Mattiuzzi GN, Giles F. Fungal infections of the central nervous system in patients with hematologic malignancies. BJH 131:287-300, 2005.

Abstracts

1. Mattiuzzi G, Cabanillas M, Hernandez M, Cortes J, Giles F, Estey E, Kantarjian H. Breakthrough Candida infections in patients with leukemia: the impact of antifungal prophylaxis on Candida species. Focus on Fungal Infections 16 Abstracts:190 (#P-032), 2006.

2. Cabanillas M, Thomas D, Kantarjian H, Mattiuzzi G, Bekele B, Foudray M, Cassat J, Cortes J. Epoetin alfa vs standard of care decreases number of packed red blood cell transfusions in patients receiving hyper-CVAD for acute lymphocytic leukemia, lymphoblastic lymphoma, and Burkitt's lymphoma. Blood 108(11):197b (#4476), 2006.

3. Mattiuzzi G, Cortes J, Faderl S, Cabanillas M, Giles F, O'Brien S, Garcia-Manero G, Kantarjian H. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome teated with targeted therapy may benefit from prophylactic measures against infections. Blood 108(11):197b (#4483), 2006.

4. Mattiuzzi G, Cortes J, Cassat J, Blamble D, Bekele BN, Borthakur G, Ravandi F, Burger J, Kantarjian H. An interim analysis of phase II, open randomized comparative trial: alternate or multiple-day dosing of palonosetron is effective and safe in the prevention of chemotherapy induced nausea and vomiting in patients with leukemia receiving high dose ara-c. Blood 110(11):835a (#2840), 11/2007.

5. Jain N, Mattiuzzi G, Cortes J, Cassat J, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Borthakur G, O'Brien S, Kantarjian H. Benefit of anti-infectious propylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline "targeted therapy." Blood 110(11):841a (#2858), 11/2007.

6. Mattiuzzi G, Cortes J, Blamble D, Estey E, Kantarjian H. Liposomal amphotericin B IV once per week is effective in the prevention of invasive fungal infections in patients with acute leukemia: preliminary analysis of a randomized trial. Blood 110(11):540a (#1824), 11/2007.

7. Alvarado Y, Kantarjian H, Verma D, Mattiuzzi G, Aribi A, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoiesis-stimulating agents in patients with chronic myeloid leukemia treated with imatinib. Blood 110(11):869a (#2959), 11/2007.

8. Chemaly RF, Sharma P, Hanmod S, Mattiuzzi G, Cabanillas M, Kantarjian H, Safdar A, Raad I. Cytomegalovirus infection in patients with acute leukemia. 45th IDSA Abstracts, 2007.

9. Mattiuzzi G, Kantarjian H, Odabasi Z, Alvarado G, Cassat J, Paetznick V, Rodriguez J, Chen E, Ostrosky-Zeichner L. Diagnostic performance of serum galactomannan and beta glucan in a cohort of 395 patients with acute leukemia on antifungal prophylaxis. 47th ICAAC Abstracts, 2007.

10. Cabanillas M, Thomas D, Kantarjian H, Mattiuzzi G, Bekele B, Foudray M, Cassat J, Cortes J. Epoetin alpha compared to standard of care decreases number of packed red blood cell transfusions in patients receiving hyper-CVAD for acute lymphocytic leukemia, lymphoblastic lymphoma and Burkitt's lymphoma. Pro ASCO 25(18S):375S (#7075), 2007.

11. Mattiuzzi G, Cassat J, DelBianco G, Cortes J, Kantarjian H. Secondary prophylaxis in patients with acute leukemia and invasive mold infections. 47th ICAAC Abstracts, 2007.

12. Alameri A, Koller C, Pierce S, Mattiuzzi G. Acute pulmonary hemorrhage in patients with acute myeloid leukemia during remission induction chemotherapy. Blood 112(11) (#4031), 11/2008.

13. Mattiuzzi G, Kantarjian H, Cabanillas M, Foudray M, Garris R, O'Brien S, Thomas D, Cortes J. Epoetin alfa reduces the need for red blood cell transfusions and does not affect remission rate or survival when given to patients with hematologic malignancies receiving hyper-CVAD therapy. Blood 112(11) (#903), 11/2008.

14. Mattiuzzi G, Cortes J, Xiao L, Pierce S, Kantarjian H. Outcome and predictive factors of patients with hematologic malignancies admitted to the intensive care unit. Blood 112(11) (#3986), 11/2008.

15. Mattiuzzi G, Greenberg E, Pierce S, Cortes J, Freireich E, O'Brien S, Kantarjian H. Relaxing the protected environment has not adversely impacted early outcome of older patients with AML and HR-MDS receiving induction therapy. Blood 112(11) (#3988), 11/2008.

16. Ostrosky-Zeichner L, Mattiuzzi G, Xiao L, Kantarjian H, Rodriguez J, Chen E, Paetznick V. Preliminary report of a possible association of voriconazole with false positive (1,3)-b-D-glucan

(BG): Important implications for diagnosis, therapeutic monitoring, and research. Focus On Fungal Infections 18 (#61.00), 2008.

17. Mattiuzzi G, Lahoti A, Salahudeen A, Ravandi F, Cortes J, Vu K, Kantarjian H. An assessment of the RIFLE criteria for acute kidney injury and mortality in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 114(22) (#1013), 11/2009.

18. Mattiuzzi G, Kantarjian H, Ho J, Garcia-Manero G, Cortes J. Antifungal prophylaxis for patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing intensive chemotherapy: an experience with 730 patients. Blood 114(22) (#3102), 11/2009.

19. Mattiuzzi G, Amin H, Kantarjian H, Garcia-Manero G, Cortes J. Baseline serum ferritin predicts rate of infection in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 114(22) (#1611), 11/2009.

20. Mattiuzzi G, Cortes J, McCue D, Bekele B, Xiao L, Borthakur G, Kantarjian H. Palonosetron given daily for up to 5 days is significantly better than ondansetron in the prevention of delayed CINV in patients with acute myelogenous leukemia. Blood 114(22) (#993), 11/2009.

21. Mattiuzzi G, Cortes J, Ho J, Kantarjian H. Ten years of experience with invasive aspergillosis: has anything changed? Blood 114(22) (#3687), 11/2009.

22. Malik A, Cortes JE, Kantarjian H, Mattiuzzi G, Iliescu G, Ferrajoli A, Borthakur G, Kadia T, O'Brien S. Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib. Blood 116:Abstr 4490, 11/2010.

23. Mattiuzzi G, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Faderl S, Kadia T, Estrov Z, Iliescu G, Pierce S, Cortes JE. Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem? Blood 116:Abstr 2710, 11/2010.

24. Al-Ameri A, Cortes J, Kantarjian H, Burton E, Quintas-Cardama A, Jabbour E, Badoux X, O'Brien S, Mattiuzzi G. Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure. Blood 116:Abstr 1233, 11/2010.

Book Chapters

1. Mattiuzzi G, Ostrosky-Zeichner L. Fungal and Parasitic Infections. In: Managing Infectious in Patients with Hematological Malignancies: Contemporary Hematology. Ed(s) M Kleinberg. Humana Press: New York, 113-134, 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Mattiuzzi GN, Kantarjian H. The Journal of Invasive Fungal Infections: Antifungal prophylaxis in patients with hematological cancers. 1, 1. Ed(s) J. Perfect, Z. Kanafani. Remedica: London, England, 10-16, 1/2007.

EDITORIAL AND REVIEW ACTIVITIES

Journal Reviewer

Reviewer, British Journal of Hematology, Blackwell Publishing, 2005 2011

Reviewer, Cancer, Wiley-Blackwell, Inc, 2005 2011

Reviewer, Leukemia and Lymphoma, Taylor & Francis, 2005 2011

Reviewer, Mycoses, Blackwell Publishing, 2006 2011

Reviewer, The Lancet Infectious Diseases, Elsevier, 2010 2011

TEACHING

Teaching - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Lecturer, Antifungal prophylaxis in patients with acute leukemia: our experience with intravenous itraconazole. BMT Departmental Meeting

4/2002

Lecturer, Antifungal prophylaxis in patients with leukemia: to be or not to be. Current Concepts in Hematology/Oncology for Nurses

4/2002

Lecturer, Pneumonia in patients with leukemia. Current Concepts in Hematology/Oncology for Nurses

8/2004

Lecturer, Principles of Therapeutics/Fungi and human diseases, GSBS, Course Hours: 1

Spring, 2/2010

Other Formal Teaching

Postdoctoral Research Fellows

Research Mentor, Gladys Alvarado, MD, 6/2002 10/2004

Research Mentor, Gabriela Del Bianco, MD, 6/2004 6/2005

Teaching Outside of Current Institution

Formal Teaching

Other Formal Teaching

Lecturer, Physician experience utilizing itraconazole, OrthoBiotech Sporanox School

6/2002

Lecturer, Antifungal prophylaxis in high-risk patients, Enzon National Educational Meeting

3/2003

Lecturer, Antifungal prophylaxis in high-risk patients, Enzon National Educational Meeting

9/2003

Lecturer, Fungal infections in patients with hematologic malignancies: the last recap, Gilead National Educational Meeting

6/2004

CONFERENCES AND SYMPOSIA

Presentations at National or International Conferences

Invited

Amphotericin B lipid complex in patients with hematological malignancies and proven fungal infection, oral presentation, First Meeting of the European Haematology Association, Brussels, Belgium, 6/3/1994

Systemic fungal infections in hematological malignancies patients: Manageable with less toxicity?, Challenging Contemporary Practices in the Management of Systemic Fungal Infections Symposium; First Meeting of the European Haematology Association, Brussels, Belgium, 6/3/1994

Infectious complications of CD8 depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia, poster presentation, 19th Congress of European Society for Medical Oncology, Lisbon, Portugal, 11/18/1994

Tratamiento de las enfermedades por hongos, Servicio de Hematologia y Oncologia Medica, Hospital Universitat de Valencia, Valencia, Spain, 11/24/1994

Tratamiento de las infecciones en el transplante de Medula Osea, Servicio de Hematologia y Oncologia Medica, Hospital Universitat de Valencia, Valencia, Spain, 11/25/1994

Infecciones en pacientes inmunocomprometidos, Colegio de Medicos de San Carlos de Bariloche, San Carlos de Bariloche, Argentina, 11/23/1995

Complicaciones infecciosas en pacientes con transplante de Medula Osea, Colegio de Medicos de San Carlos de Bariloche, San Carlos de Bariloche, Argentina, 8/31/1996

Advances in Treating Fungal Infections, Visiting Professor Program, Mercy Medical Center, Oncology and Pulmonary, Redding, CA, 7/30/2002

Emerging Fungal Infections, Hispanic Medical Society, San Antonio, TX, 9/10/2004

Emerging Fungal Infections, Advances and Challenges in Hematologic Malignancies, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/8/2004

Contact this candidate